Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,888,313
  • Shares Outstanding, K 55,230
  • Annual Sales, $ 20,530 K
  • Annual Income, $ -133,750 K
  • 60-Month Beta 1.99
  • Price/Sales 95.52
  • Price/Cash Flow N/A
  • Price/Book 8.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.68
  • Number of Estimates 6
  • High Estimate -0.49
  • Low Estimate -0.88
  • Prior Year -0.66
  • Growth Rate Est. (year over year) -3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.87 +20.12%
on 07/24/20
39.96 -13.21%
on 08/06/20
+1.81 (+5.49%)
since 07/10/20
3-Month
23.51 +47.51%
on 05/13/20
39.96 -13.21%
on 08/06/20
+9.20 (+36.13%)
since 05/12/20
52-Week
14.01 +147.54%
on 03/16/20
39.96 -13.21%
on 08/06/20
+10.64 (+44.26%)
since 08/12/19

Most Recent Stories

More News
Editas' (EDIT) Earnings Beat in Q2, Revenues Improve Y/Y

Editas' (EDIT) both bottom and the top line better estimates for the second quarter of 2020.

EBS : 129.78 (+6.09%)
ABBV : 95.36 (+2.90%)
EDIT : 34.69 (+1.46%)
CTLT : 87.62 (+3.20%)
Editas: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Editas Medicine Inc. (EDIT) on Thursday reported a loss of $23.6 million in its second quarter.

EDIT : 34.69 (+1.46%)
Editas Medicine Announces Second Quarter 2020 Results and Update

Regained full control of ocular medicines under new agreement with AbbVie

EDIT : 34.69 (+1.46%)
Editas Medicine Regains Full Global Rights to Ocular Medicines

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced it has regained full global rights to research, develop, manufacture, and commercialize its ocular medicines, including...

AGN : 193.02 (+0.02%)
EDIT : 34.69 (+1.46%)
CRISPR Technology Global Market Report 2020-30: Covid 19 Growth and Change

, /PRNewswire/ -- Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery Plc., Integrated...

CRSP : 91.51 (+2.30%)
EDIT : 34.69 (+1.46%)
Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs,...

EDIT : 34.69 (+1.46%)
Editas Medicine Appoints Gad Berdugo as Chief Business Officer

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has named Gad Berdugo as the Company's Chief Business Officer. Mr. Berdugo will oversee the Company's business...

EDIT : 34.69 (+1.46%)
Editas Medicine to Host Conference Call Discussing Second Quarter 2020 Results and Corporate Update

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, August 6, 2020, at 5:00 p.m. ET to discuss a corporate...

EDIT : 34.69 (+1.46%)
Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the closing of its previously announced underwritten offering of 6,900,000 shares of its common stock at a public...

EDIT : 34.69 (+1.46%)
Worldwide CRISPR Market to 2028 - Key Drivers, Restraints, Opportunities and Challenges

, /PRNewswire/ -- The report has been added to offering.

CMVLF : 17.7600 (+3.62%)
DCYHY : 18.5200 (unch)
EDIT : 34.69 (+1.46%)
MKKGY : 27.3450 (+3.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade EDIT with:

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 36.69
1st Resistance Point 35.44
Last Price 34.69
1st Support Level 33.46
2nd Support Level 32.73

See More

52-Week High 39.96
Last Price 34.69
Fibonacci 61.8% 30.05
Fibonacci 50% 26.99
Fibonacci 38.2% 23.92
52-Week Low 14.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar